Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03809663
Recruitment Status : Recruiting
First Posted : January 18, 2019
Last Update Posted : October 3, 2019
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Amgen

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 3, 2021
Estimated Study Completion Date : July 3, 2021